Key Highlights

  • Quarterly Revenue reached USD 64.1 million, of which IM8 supplied USD 62.9 million.
  • IM8 revenue hit USD 23.7 million in September, the strongest month on record.
  • Adjusted free Cash Flow turned positive at USD 4.1 million.
  • Second-half adjusted EBITDA loss is now guided at USD 30 million to USD 35 million.

Prenetics (NASDAQ:PRE) has decided to spend more on growth, and its guidance now reflects that. The company expects a second-half adjusted EBITDA loss of USD 30 million to USD 35 million, against the USD 8 million to USD 12 million it gave in August, and it describes the increase as deliberate. The chief executive said the company is putting more money behind growth, citing what it earns from acquiring customers. The company added that the Business generated USD 30.6 million ahead of Acquisition Marketing and Brand partner costs during the period.

Revenue, Cash and Customer Returns

Third-quarter 2026 revenue was USD 64.1 million, ahead of an estimated USD 63.40 million. IM8 contributed USD 62.9 million, almost 40% more than in the second quarter, and the company said its revenue has now grown for six consecutive quarters. EPS was negative USD 1.43 against an estimated negative USD 0.96.

September was the strongest month on record, with USD 23.7 million of IM8 revenue, an annualized run rate of USD 284 million by the company's reckoning. Adjusted free cash flow turned positive at USD 4.1 million, because USD 31.6 million of net funding from General Catalyst more than covered the USD 27.5 million of cash used in operations.

Management put numbers on what each marketing dollar buys. Across the first six quarters of 2026, every dollar spent on acquiring customers has returned USD 1.68 of gross profit, compared with about USD 1.44 in July. The earliest cohort, made up of 27,000 customers acquired in the first quarter of 2025, has returned USD 4.10 per dollar. Customer acquisition cost declined for the second quarter running, to about USD 285.

Subscriptions, Partners and Products

Repeat orders accounted for about 59% of customer billings, and the company finished September with roughly 160,000 active subscriptions. More than 52,000 new customers arrived in September alone. Among its partners is a football star who serves as co-founder, and in October it was named Official Nutrition Partner of the NBA in Australia and eight Southeast Asian markets.

The product calendar has shifted. IM8 Hydration moved to the first quarter of 2027, while Care Bears by IM8, launched under a 10-year exclusive Partnership with Authentic Brands Group, is targeted for the second quarter of 2027. Three randomized placebo-controlled trials are under way, with results targeted for the first half of 2027.

Financing, Guidance and Items to Follow

It was the first complete quarter operating under a USD 1 billion growth financing commitment from General Catalyst, which funded 70% of customer acquisition spend. The company reaffirmed 2027 revenue guidance of USD 400 million, a figure that excludes Hydration, Care Bears, retail and China. A new chief financial officer will take over from the current one on December 31.

Spending would be slowed, management said, if either customer acquisition cost or cohort returns moved the wrong way. Those two measures, the Hydration launch and the scale of the second-half loss are the points to follow. Management put its 0.14% share of a USD 200 billion category forward as a gauge of the opportunity.